USPTO serial 85639079
PILLIE
Reviewed by CopyMark Law Group
Reg. 4394743Status 710
- Filing date
- Status date
- Registration date
- Sep 3, 2013
- Examiner
- JOINER, KATINA JACKSON
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with PILLIE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Dietary and nutritional supplements; Dietary and nutritional supplements containing a vitamin, a mineral, an herb or other botanical extract; an amino acid for nutritional purposes; dietary concentrate, metabolite, constituent or extract for use by man to supplement the diet by increasing the total dietary intake; Dietary supplements for human consumption; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Herbal supplements; Natural herbal supplements; Nutraceuticals for use as a dietary supplement for Gastrointestinal, Digestive and liver support; Vitamin and mineral supplements for respiratory system support; dietary supplements for Mood, sleep, memory support; dietary supplements for Central and peripheral nervous system support; dietary supplements for Vision support, Hearing support, Cardiovascular support, Metabolic support; dietary supplements for Bone, joint and muscle support; dietary supplements for Dermatologic support and Anti-aging support; nutritional supplements for Beauty, namely, hair, skin, nails support; dietary supplements for Hormone and endocrine support, Weight management/support, Blood sugar support, Energy support, Immune support, Respiratory support, Men's health and Women's health; dietary supplements for Exercise and physical performance support; dietary supplements for Infant, toddler, children nutritional support; dietary supplements for Geriatric health and support; dietary supplements for Urinary support; Natural Product Extracts in the nature of plant extracts for medical purposes; dietary supplements for Anti-inflammatory support; dietary supplements for Lipid support and Anti-oxidant support; dietary and nutritional supplements containing Greens, Fibers, Fruits, Vegetables, and superfoods; dietary Fibers for treating constipation; fruit-based Meal replacement bars for medical purposes; Amino Acids for nutritional purposes; Nutritional supplements, namely, carbohydrates in powdered form; Protein and peptide formulas for use as dietary and nutritional supplements; Prebiotics/Probiotics; Nutritional supplements in the form of solid dosage forms, semi-solid dosage forms, liquid dosage forms and parenteral dosage forms; Pharmaceutical preparations for Alzheimer's Dementia treatment; pharmaceutical preparations in the nature of Amoebicides/Antiprotozoals; Anabolic/Androgenic Steroids; Analeptic drugs; Analgesics/Anti-pyretics; Anesthetic Agent for surgical and non-surgical use; Antacids/Antiflatulents; pharmaceutical preparations, namely, Anthelmintics; Anti-Arthritis preparations; Anti-Inflammatory Drugs; Anti-Tuberculosis Drugs; Anti-acne/Anti-psoriatic Drugs; Anti-allergic Drugs; Antibiotics/Antibacterials; Anticancer Drugs; Anti-coagulant and Antithrombotic Agents; pharmaceutical preparations, namely, Anti-convulsants; pharmaceutical preparations, namely, Anti-depressants; Anti-diabetic drugs; Antidiarrheals; pharmaceutical preparations in the nature of Anti-emetics; Anti-epileptic pharmaceutical preparations; Anti-fungal preparations; Antiinfectives; Anti-malarials; Anti-migraine Drugs; Antiobesity Drugs; Anti-osteoporotic Agents; Anti-Parkinson's drugs; Anti-psychotic drugs; Anti-retroviral drugs; Anti-spasmodics drugs; Antitussive drugs; pharmaceutical preparations, namely, Anti-ulcerants; Antivirals; Anxiolytics/Sedatives; Appetite Stimulants; Benign Prostatic Hyperplasia Drugs; Biologics and Biosimilars for the treatment of respiratory diseases; pharmaceuticals in the nature of Birth Control preparations; pharmaceuticals in the nature of Cardiovascular Agents; Cognitive and ADHD drugs; pharmaceutical preparations in the nature of cholesterol and Hypolipedemic Agents; pharmaceutical preparations for Cough and Cold treatment; Diuretics; Electrolyte Solutions for the treatment of respiratory diseases, namely, cough, cold, and asthma; pharmaceuticals for Erectile Dysfunction Therapy; Expectorants/Cold Preparations/Mucolytes; pharmaceuticals in the nature of Eye and Ear Preparations; pharmaceuticals for the treatment of Gastroenterology issues; pharmaceuticals in the nature of Glucose solutions for the treatment of respiratory diseases; pharmaceuticals, namely, Gout Preparations; pharmaceuticals, namely, Haematinic Preparation; pharmaceuticals, namely, Haemorrhoelogic Agents; pharmaceuticals, namely, Haemostatics; pharmaceutical preparations for Hormone Treatment; pharmaceuticals, namely, Hormone Replacement Therapy; pharmaceutical preparations for Inflammation and Immunology; pharmaceuticals, namely, Immunosuppressants; Inhaler drugs for the treatment of respiratory diseases; Intranasal agents for the treatment of respiratory diseases; Intravenous drugs for the treatment of respiratory diseases; Iron Chelators; pharmaceuticals for the treatment of Irritable Bowel Syndrome; Nasal Preparations for the treatment of respiratory diseases; pharmaceutical preparations in the nature of Non-steroidal anti-inflammatory agents for the treatment of respiratory disease; OTC drugs for the treatment of respiratory diseases; Otic drugs for the treatment of respiratory diseases; Ophthalmologic drugs and preparations; pharmaceutical preparations for Pain Treatment; pharmaceutical preparations for Palliative Treatment; Poison antidotes; Psychiatric and psychotropic drugs; Respiratory Drugs, namely, pharmaceutical products for treating respiratory diseases; Saline Solutions for medical purposes; Sedative/Hypnotics; Small Molecule drugs for the treatment of respiratory diseases; Skeletal Muscle Relaxant; pharmaceutical preparations for the treatment of Sexually transmitted diseases; Suppository drugs; Systemic Corticosteroids; Topical Anti- Infectives; Topical Corticosteroids; Topical Preparations for the treatment of respiratory diseases; pharmaceutical preparations in the nature of Urinary Smooth Muscle Contractor; Urinary Smooth Muscle Relaxants; Uterine Stimulants; Vaccines; Vertigo Treatments; Vitamins and Mineral drugs, solutions and preparations; Wart Treatments | SECTION 8 - CANCELLED | May 29, 2012 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 5, 2020 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Sep 3, 2018 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Sep 3, 2013 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 18, 2013 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 18, 2013 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 29, 2013 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 13, 2013 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| May 6, 2013 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 2, 2013 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 2, 2013 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 1, 2013 | ALIE | ASSIGNED TO LIE | — |
| Mar 30, 2013 | NREV | NOTICE OF REVIVAL - E-MAILED | — |
| Mar 30, 2013 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 30, 2013 | PETG | PETITION TO REVIVE-GRANTED | — |
| Mar 30, 2013 | PROA | TEAS PETITION TO REVIVE RECEIVED | — |
| Sep 24, 2012 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 24, 2012 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 24, 2012 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 17, 2012 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 8, 2012 | MDSC | NOTICE OF DESIGN SEARCH CODE MAILED | — |
| Jun 7, 2012 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 2, 2012 | NWAP | NEW APPLICATION ENTERED | — |